According to Chang et al., increased PD-L1 on cancer cells increases mTOR function and glycolysis (Figure 2), leading to cancer-driven glucose limitation, changes CD8+ T-cell metabolism, and reduces T cell’s ability to produce IFN-γ (107). The gene discussed is IFNG; the disease is cancer.